Active Ingredient: ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE
Proprietary Name: OSENI
Dosage Form; Route of Administration: TABLET; ORAL
Strength: EQ 12.5MG BASE;EQ 15MG BASE
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N022426
Product Number: 004
Approval Date: Jan 25, 2013
Applicant Holder Full Name: TAKEDA PHARMACEUTICALS USA INC
Marketing Status:
Prescription
Patent and Exclusivity Information
Active Ingredient: ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE
Proprietary Name: OSENI
Dosage Form; Route of Administration: TABLET; ORAL
Strength: EQ 12.5MG BASE;EQ 30MG BASE
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N022426
Product Number: 005
Approval Date: Jan 25, 2013
Applicant Holder Full Name: TAKEDA PHARMACEUTICALS USA INC
Marketing Status:
Prescription
Patent and Exclusivity Information
Active Ingredient: ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE
Proprietary Name: OSENI
Dosage Form; Route of Administration: TABLET; ORAL
Strength: EQ 12.5MG BASE;EQ 45MG BASE
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N022426
Product Number: 006
Approval Date: Jan 25, 2013
Applicant Holder Full Name: TAKEDA PHARMACEUTICALS USA INC
Marketing Status:
Prescription
Patent and Exclusivity Information
Active Ingredient: ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE
Proprietary Name: OSENI
Dosage Form; Route of Administration: TABLET; ORAL
Strength: EQ 25MG BASE;EQ 15MG BASE
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N022426
Product Number: 001
Approval Date: Jan 25, 2013
Applicant Holder Full Name: TAKEDA PHARMACEUTICALS USA INC
Marketing Status:
Prescription
Patent and Exclusivity Information
Active Ingredient: ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE
Proprietary Name: OSENI
Dosage Form; Route of Administration: TABLET; ORAL
Strength: EQ 25MG BASE;EQ 30MG BASE
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N022426
Product Number: 002
Approval Date: Jan 25, 2013
Applicant Holder Full Name: TAKEDA PHARMACEUTICALS USA INC
Marketing Status:
Prescription
Patent and Exclusivity Information
Active Ingredient: ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE
Proprietary Name: OSENI
Dosage Form; Route of Administration: TABLET; ORAL
Strength: EQ 25MG BASE;EQ 45MG BASE
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N022426
Product Number: 003
Approval Date: Jan 25, 2013
Applicant Holder Full Name: TAKEDA PHARMACEUTICALS USA INC
Marketing Status:
Prescription
Patent and Exclusivity Information